Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

510(k) Guidance Footnote May Signal Greater FDA Oversight Of Preclinical Testing

This article was originally published in The Gray Sheet

Executive Summary

Device industry experts say a seemingly minor footnote to the recent 510(k) program draft guidance could create a new requirement for nonclinical studies.

You may also be interested in...



510(k)s Are Subject To Good Laboratory Practice Regs – FDA Draft Guidance

Device manufacturers must declare compliance or explain noncompliance to good laboratory practice regulations for nonclinical studies in all premarket submission types, according to new draft guidance. This has not been the requirement for 510(k)s up until now, says the former CDRH 510(k) policy chief.

510(k)s Are Subject To Good Laboratory Practice Regs – FDA Draft Guidance

Manufacturers must declare compliance or explain noncompliance to good laboratory practice regulations for nonclinical studies in all pre-market submission types, according to a new draft guidance. This has not been the requirement for 510(k)s up until now, says the former CDRH 510(k) policy chief.

Not So Special? FDA Proposal Would Damage Streamlined 510(k) Submissions Program, Firms Say

Agency’s proposed “special 510(k)” reforms, outlined in a recent draft guidance, will make the streamlined submissions program a lot less streamlined, and also less accessible to many device modifications, companies say.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT030894

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel